National Institute on Drug Abuse; Notice of Meeting, 14176 [2010-6264]
Download as PDF
<![CDATA[
14176
Federal Register / Vol. 75, No. 56 / Wednesday, March 24, 2010 / Notices
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Substance Abuse Treatment Referral System
(5543).
Date: May 11, 2010.
Time: 1:30 p.m. to 3 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6101
Executive Boulevard, Rockville, MD 20852,
(Telephone Conference Call).
Contact Person: Lyle Furr, Contract Review
Specialist, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH,
DHHS, Room 220, MSC 8401, 6101 Executive
Boulevard, Bethesda, MD 20892–8401, (301)
435–1439, lf33c.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: March 16, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–6266 Filed 3–23–10; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
srobinson on DSKHWCL6B1PROD with NOTICES
National Institute on Drug Abuse;
Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Council on Drug
Abuse.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council on Drug Abuse.
VerDate Nov<24>2008
16:24 Mar 23, 2010
Jkt 220001
Date: May 5, 2010.
Closed: 8:30 a.m. to 10 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
Open: 11 a.m. to 2 p.m.
Agenda: This portion of the meeting will
be open to the public for announcements and
reports of administrative, legislative and
program developments in the drug abuse
field.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
Contact Person: Teresa Levitin, PhD,
Director, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH,
DHHS, Room 220, MSC 8401, 6101 Executive
Boulevard, Bethesda, MD 20892–8401, (301)
443–2755.
Any member of the public interested in
presenting oral comments to the committee
may notify the Contact Person listed on this
notice at least 10 days in advance of the
meeting. Interested individuals and
representatives of organizations may submit
a letter of intent, a brief description of the
organization represented, and a short
description of the oral presentation. Only one
representative of an organization may be
allowed to present oral comments and if
accepted by the committee, presentations
may be limited to five minutes. Both printed
and electronic copies are requested for the
record. In addition, any interested person
may file written comments with the
committee by forwarding their statement to
the Contact Person listed on this notice. The
statement should include the name, address,
telephone number and when applicable, the
business or professional affiliation of the
interested person.
Information is also available on the
Institutes/Center’s home page: https://
www.drugabuse.gov/NACDA/
NACDAHome.html, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: March 16, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–6264 Filed 3–23–10; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
Statement of Organization, Functions,
and Delegations of Authority
Part F of the Statement of
Organization, Functions, and
Delegations of Authority for the
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Department of Health and Human
Services, Centers for Medicare &
Medicaid Services (CMS), (Federal
Register, Vol. 72, No. 248, pp. 73847–
73850, dated Friday, December 28,
2007) is amended to reflect changes to
the current structure of CMS.
In an effort to improve the value and
service that CMS provides to the Nation,
the CMS has modified its structure to
align similar functions under common
executive leadership and allow CMS to
establish a Center for Program Integrity
and to strengthen its focus on
beneficiary services and strategic
planning.
The structure includes the following,
which all report to the Administrator,
CMS: (1) Center for Medicare, (2) Center
for Medicaid, CHIP and Survey &
Certification, (3) Center for Strategic
Planning, (4) Center for Program
Integrity, and (5) Office of External
Affairs and Beneficiary Services. In
addition, the current role of the Chief
Operating Officer (COO) has been
formalized and remains responsible for
operations, information systems,
contracts, finance, E-health standards
and services, and the Consortia. The
COO continues to report to the
Administrator, CMS. The following
organizations remain substantively
unchanged and continue to report to the
Administrator, CMS: Office of Equal
Opportunity and Civil Rights, Office of
Legislation, Office of the Actuary, Office
of Clinical Standards and Quality, and
the Office of Strategic Operations and
Regulatory Affairs (will be renamed the
Office of Executive Operations and
Regulatory Affairs to more accurately
reflect the work of the organization).
New administrative codes were assigned
to all organizations, including the
immediate office of the Administrator.
Given the complexity and importance
of CMS’ programs, this realignment of
existing functions positions CMS to
consistently excel in serving our
beneficiaries and strategically positions
CMS for the future. Additionally, this
effort ensures common core functions
are under common executive leadership
and share a consistent vision.
The specific amendments to Part F
are described below:
I. Under Part F, CMS, Office of the
Administrator, FA.10 Organization is
deleted in its entirety and replaced with
the following:
FC.10 Organization. CMS is headed
by the Administrator, CMS, and
includes the following organizational
components:
Office of the Administrator (FC)
Office of Equal Opportunity and Civil
Rights (FCA)
E:\FR\FM\24MRN1.SGM
24MRN1
]]>Agencies
[Federal Register Volume 75, Number 56 (Wednesday, March 24, 2010)]
[Notices]
[Page 14176]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-6264]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
National Advisory Council on Drug Abuse.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Advisory Council on Drug Abuse.
Date: May 5, 2010.
Closed: 8:30 a.m. to 10 a.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852.
Open: 11 a.m. to 2 p.m.
Agenda: This portion of the meeting will be open to the public
for announcements and reports of administrative, legislative and
program developments in the drug abuse field.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852.
Contact Person: Teresa Levitin, PhD, Director, Office of
Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS,
Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-
8401, (301) 443-2755.
Any member of the public interested in presenting oral comments
to the committee may notify the Contact Person listed on this notice
at least 10 days in advance of the meeting. Interested individuals
and representatives of organizations may submit a letter of intent,
a brief description of the organization represented, and a short
description of the oral presentation. Only one representative of an
organization may be allowed to present oral comments and if accepted
by the committee, presentations may be limited to five minutes. Both
printed and electronic copies are requested for the record. In
addition, any interested person may file written comments with the
committee by forwarding their statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institutes/Center's home
page: https://www.drugabuse.gov/NACDA/NACDAHome.html, where an agenda
and any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: March 16, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-6264 Filed 3-23-10; 8:45 am]
BILLING CODE 4140-01-M
